- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01677780
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
July 5, 2017 updated by: Hoffmann-La Roche
A Multi-Center, Open-Label, Extension Study of RO5045337 (MDM2 Antagonist) Administered Orally in Patients Treated With RO5045337 on Previous Roche-Sponsored Phase 1 Cancer Studies
This open-label, extension study is designed to provide continuing treatment with RO5045337 to participants who have completed parent studies NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296).
Participants are eligible to participate in this study if they have completed required Phase 1 study assessments for primary objectives of respective parent protocol and are having evidence of clinical benefit (as defined by the parent protocol).
Participants will continue the most similar dose and formulation available (which does not exceed the maximum tolerated dose [MTD] or the maximum safely administered dose for that formulation during Phase 1) and the same schedule of RO5045337 treatment that they were receiving at the time of transitioning from the parent clinical study protocol.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Hospital, Medical Oncology & Haematology
-
-
-
-
-
Toulouse, France, 31059
- Institut Claudius Regaud; Departement Oncologie Medicale
-
-
-
-
California
-
Santa Monica, California, United States, 90403
- Sarcoma Oncology Center
-
-
Texas
-
Houston, Texas, United States, 77030
- M.D Anderson Cancer Center; Oncology
-
San Antonio, Texas, United States, 78229
- Cancer Therapy & Research Ctr; Dept Institute for Drug Development
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants must meet the inclusion criteria outlined in the respective parent protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296)
- Participants must have completed one of the following clinical study protocols and have been determined to have clinical benefit on treatment at the conclusion of required study analyses as defined in the respective parent protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296)
Exclusion Criteria:
- Participants must meet the exclusion criteria outlined in the respective parent protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296)
- Participants who developed disease progression/ requiring other anti-tumor therapy while in the parent protocol
- Participants who have stopped study drug dosing for greater than 56 days
- Participants continuing to require dose modifications
- Participants with worsening adverse events
- Participants with unrelated adverse events, medical illnesses, or changes in performance status that, per investigator discretion, put them at high risk for continuing participation in the clinical study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: RO5045337
Participants will continue the most similar dose and formulation available (which does not exceed the MTD or the maximum safely administered dose for that formulation during Phase 1) and the same schedule of RO5045337 treatment that they were receiving at the time of transitioning from their respective parent clinical study protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296).
|
Participants will receive RO5045337 orally in doses ranging from 20 milligram per square meter (mg/m^2) to 1800 mg/m^2 daily, and up to 1500 mg dose twice daily on a variety of schedules including daily for up to 20 days and weekly dosing for 3 weeks in 28 day cycles until disease progression or unacceptable toxicity with maximum treatment duration of 24 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Approximately 24 months
|
Approximately 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 28, 2012
Primary Completion (ACTUAL)
June 26, 2017
Study Completion (ACTUAL)
June 26, 2017
Study Registration Dates
First Submitted
August 30, 2012
First Submitted That Met QC Criteria
August 30, 2012
First Posted (ESTIMATE)
September 3, 2012
Study Record Updates
Last Update Posted (ACTUAL)
July 7, 2017
Last Update Submitted That Met QC Criteria
July 5, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NP28366
- 2012-001303-20 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Immunex CorporationWithdrawnAcute Myelogenous Leukemia | Chronic Myelogenous Leukemia
-
Masonic Cancer Center, University of MinnesotaCompletedRelapsed Acute Myelogenous Leukemia | Refractory Acute Myelogenous LeukemiaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedAccelerated Phase Chronic Myelogenous Leukemia | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent... and other conditionsUnited States
-
Baylor Research InstituteCompletedMyelodysplastic Syndromes | Acute Myelogenous Leukemia | Chronic Myelogenous LeukemiaUnited States
-
Dana-Farber Cancer InstituteBoston Children's Hospital; Brigham and Women's HospitalCompletedMyelogenous Leukemia, AcuteUnited States
-
Cooperative Study Group A for HematologyCompletedACUTE MYELOGENOUS LEUKEMIAKorea, Republic of
-
M.D. Anderson Cancer CenterActive, not recruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase...United States
-
Therapeutic Advances in Childhood Leukemia ConsortiumGenzyme, a Sanofi CompanyTerminatedRelapsed Acute Myelogenous LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Accelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic... and other conditionsUnited States
-
University of TexasCompletedAcute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia
Clinical Trials on RO5045337
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedHematologic NeoplasmsUnited States, Canada, United Kingdom, Italy
-
Hoffmann-La RocheCompletedNeoplasmsFrance, United States
-
Hoffmann-La RocheCompleted
-
Shimaa M. AbdelgawadCompletedCovid19 | COVID-19 Respiratory Infection | Symptoms and Signs | Disseminated Intravascular Coagulation | COVID-19 Acute BronchitisEgypt
-
Hoffmann-La RocheCompletedSarcomaFrance, United States